Thus, the phase III randomized trial named MARIPOSA [8] was developed to test the superiority of the combination of amivantamab plus lazertinib versus osimertinib alone, with the hope that the combination would proactively counteract mechanisms of resistance to osimertinib, positively affecting the survival of patients with advanced EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.